You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 7, July 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Patient Education/ Health Literacy
 •Patient-Physician Relationship, Other
 •Quality of Life
 •Dermatologic Disorders, Other
 •Dermatology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Pictorial Representation of Illness and Self Measure (PRISM)

A Novel Visual Instrument to Measure Quality of Life in Dermatological Inpatients

Beda Mühleisen, MD; Stefan Büchi, MD; Simone Schmidhauser; Josef Jenewein, MD; Lars E. French, MD; Günther F. L. Hofbauer, MD

Arch Dermatol. 2009;145(7):774-780.

Objectives  To validate the PRISM (Pictorial Representation of Illness and Self Measure) tool, a novel visual instrument, for the assessment of health-related quality of life in dermatological inpatients compared with the Dermatology Life Quality Index (DLQI) and the Skindex-29 questionnaires and to report qualitative information on PRISM.

Design  In an open longitudinal study, PRISM and Skindex-29 and DLQI questionnaires were completed and HRQOL measurements compared.

Setting  Academic dermatological inpatient ward.

Participants  The study population comprised 227 sequential dermatological inpatients on admission.

Intervention  Patients completed the PRISM tool and the Skindex-29 and DLQI questionnaires at admission and discharge.

Main Outcome Measures  PRISM Self-Illness Separation (SIS) score; Skindex-29 and DLQI scores; and qualitative PRISM information by Mayring inductive qualitative context analysis.

Results  The PRISM scores correlated well with those from the Skindex-29 ({rho} = 0.426; P < .001) and DLQI ({rho} = 0.304; P < .001) questionnaires. Between PRISM and Skindex-29 scores, the highest correlations were for dermatitis ({rho} = 0.614) and leg ulcer ({rho} = 0.554), and between PRISM and DLQI scores, the highest correlations were for psoriasis ({rho} = 0.418) and tumor ({rho} = 0.399). The PRISM tool showed comparable or higher sensitivity than quality of life questionnaires to assess changes in the burden of suffering during hospitalization. Inductive qualitative context analysis revealed impairment of adjustment and self-image as major aspects. Patients overall expected symptomatic and functional improvement. In patients with psoriasis and leg ulcers, many expected no treatment benefit.

Conclusions  The PRISM tool proved to be convenient and reliable for health-related quality of life assessment, applicable for a wide range of skin diseases, and correlated with DLQI and Skindex-29 scores. With the PRISM tool, free-text answers allow for the assessment of individual information and potentially customized therapeutic approaches.


Author Affiliations: Departments of Dermatology (Drs Mühleisen, French, and Hofbauer and Ms Schmidhauser) and Psychiatry (Drs Büchi and Jenewein), University Hospital Zürich, Zürich, Switzerland.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Quality of Life and Skin Diseases: Be Careful With Counterfeit . . . 
Jean Jacques Grob
Arch Dermatol. 2009;145(7):813-814.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Quality of Life and Skin Diseases: Be Careful With Counterfeit . . .
Grob
Arch Dermatol 2009;145:813-814.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.